25.08.2013 Views

össur annual report2009 - Euroland

össur annual report2009 - Euroland

össur annual report2009 - Euroland

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

We provide products and services to exceed<br />

customers’ expectations. Strongly focused<br />

on continuous improvement, we monitor<br />

and respond to needs, complying with all<br />

regulatory requirements.<br />

quality<br />

The Company places significant emphasis on quality.<br />

With regards to the manufacturing of medical-device<br />

products it is highly important for Össur to expand the<br />

scope of its quality control system in line with the enactment<br />

of new laws and regulations, as well as with the<br />

growth of the Company. Since 1993, Össur has had a<br />

certified quality system in place.<br />

Quality requirements imposed on Össur are rather strict<br />

because the Company’s products are classified as medical<br />

devices. All Össur products are CE-labeled to meet<br />

the requirements of the European Economic Area, and<br />

in the United States the Company’s products adhere to<br />

FDA standards. Össur complies with ISO 9001:2000 and<br />

ISO 13485:2003. In 2009, the British Standard Institution<br />

(BSI) conducted 10 external audits, all of which concluded<br />

with positive results.<br />

<strong>annual</strong> report 09<br />

16<br />

treasury &<br />

corporate<br />

development<br />

Treasury<br />

Investor<br />

Relations<br />

Legal<br />

Corporate<br />

development<br />

r&d and product<br />

developMent<br />

Össur’s strategy is to be a source of innovative, high-<br />

quality, non-invasive orthopaedic products and services.<br />

Össur’s innovative products ensure a consistently<br />

strong position in the market. The Company has always<br />

seen R&D as essential to future development and is<br />

determined to maintain its technological competency<br />

through investment in research and development. In<br />

2009, Össur’s investment in R&D amounted to 5.8% of<br />

the Company’s total sales. Fifteen new products were<br />

launched in 2009, including the second generation of<br />

the RHEO KNEE ® which has been very well received<br />

by the market. In 2009, 101 employees worked in the<br />

Company’s R&D division.<br />

corporate finance<br />

corporate<br />

planning<br />

& analysis<br />

Financial statements<br />

Management<br />

reporting<br />

Tax planning &<br />

monitoring<br />

Budgets<br />

human<br />

resources<br />

HR Management<br />

HR processes<br />

HR intelligence<br />

business<br />

information<br />

services<br />

Employee support<br />

& services<br />

Project<br />

management<br />

& consulting<br />

Business application<br />

development<br />

Infrastructure<br />

corporate finance<br />

Corporate Finance is responsible for the overall<br />

finance administration of the consolidation. Within<br />

corporate finance there are 72 employees working in<br />

Human Resources, Business Information Services,<br />

Treasury & Corporate Development and Corporate<br />

Planning & Analysis. Corporate finance is responsible for<br />

structure and platform development globally for these<br />

functions. One of the major projects within Corporate<br />

Finance in 2009 was the listing of Össur hf. on NASDAQ<br />

OMX Copenhagen.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!